RP11-400N13.2: A Protein Target for Cancer Treatment (G110806276)

Target Name: LINC02474

NCBI ID: G110806276

LINC02474

Other Name(s): RP11-400N13.2 | Long intergenic non-protein coding RNA 2474 | long intergenic non-protein coding RNA 2474

RP11-400N13.2: A Protein Target for Cancer Treatment

LINC02474 (RP11-400N13.2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the cell cycle, and its levels have been linked to the development and progression of several diseases, including cancer.

RP11-400N13.2 is a 13.2 kDa protein that is found in the nuclei of various cell types. It is a key regulator of the cell cycle, and is involved in the control of mitosis, meiosis, and the G1/S transition. RP11-400N13.2 is a nuclear protein that is targeted for degradation by the 26S rRNA-protein complex, which is responsible for removing proteins that are no longer needed in the cell.

RP11-400N13.2 has been shown to play a role in the development and progression of several diseases, including cancer. For example, studies have shown that high levels of RP11-400N13.2 are associated with poor prognosis in patients with pancreatic cancer. Additionally, RP11-400N13.2 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer.

RP11-400N13.2 has also been shown to be involved in several signaling pathways that are important for cancer development. For example, RP11-400N13.2 has been shown to be involved in the PI3K/Akt signaling pathway, which is a well-established pathway for cancer development. Additionally, RP11-400N13.2 has been shown to be involved in the TGF-β signaling pathway, which is also important for cancer development.

RP11-400N13.2 has also been shown to be a potential drug target in cancer treatment. For example, studies have shown that inhibiting RP11-400N13.2 can be an effective way to treat several types of cancer, including pancreatic, breast, and colorectal cancer. Additionally, RP11-400N13.2 has been shown to be a good candidate for targeting with small molecules, including inhibitors of the PI3K/Akt signaling pathway.

In conclusion, RP11-400N13.2 is a protein that has been shown to play a role in the development and progression of several diseases, including cancer. It is a key regulator of the cell cycle and has been shown to be involved in several signaling pathways that are important for cancer development. As a result, RP11-400N13.2 is a potential drug target for cancer treatment. Further research is needed to fully understand the role of RP11-400N13.2 in cancer development and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2474

The "LINC02474 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02474 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets